Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SPET-085 Inhibits Enzyme Linked To Benign Prostatic Hyperplasia: Euromed
The study was conducted to assess the in-vitro potency of SPET-085, an inhibitor of the 5alpha-reductase isoenzyme type II, in a cell-free test system. SPE has been used
The study was conducted to assess the in-vitro potency of SPET-085, an inhibitor of the 5alpha-reductase isoenzyme type II, in a cell-free test system. SPE has been used
Bristol-Myers informed that the lot numbers which are included in the recall are Physician Sample Blister Packs: Lot no 9A48931A, 9A48931B, 9A48931C, expiration January 2012; HUD Blister Pack:
Iowa Health said that Greenway was selected for its $21.7m program by the New York City REC, administered by the NYC Regional Electronic Adoption Center for Health (NYC
Biomagnetics claimed that the expected acquisition is the first of several planned acquisitions targeted at a $1.00 share price for company’s common shares. The company plans for rapid
Benlysta is being jointly developed under a co-development and commercialisation agreement entered into, in 2006, by HGS and GlaxoSmithKline (GSK). Belimumab is an investigational human monoclonal antibody drug
Addicere Therapeutics, a wholly-owned subsidiary of Alexza, has been launched by the company to develop all applications of the Staccato technology for the pharmaceutical uses of nicotine. Thomas
ADX71943 is a selective positive allosteric modulator of gamma-aminobutyric acid subtype B (GABA-B) receptors. GABA-B receptors mediate the slow, prolonged physiological effects of the inhibitory neurotransmitter GABA and
Clinuvel Pharma claimed that it had to develop new study methodology along with EPP experts to be able to evaluate Scenesse, in this 12 month European and Australian
Making use of HighRes dual NanoCell system, which includes two AmbiStore high-speed carousels of HighRes, Rigel is expected to perform cell-based, biochemical, and high-content screening assays against a
The current development is a part of a research agreement signed in 2005 between Ablynx and Novartis, and has been extended by mutual agreement last year. Novartis is